BenevolentAI

The AI-driven drug discovery sector is reducing costs, increasing speed and improving precision in targeting and treating disease. Our chief scientific officer, Anne Phelan, spoke to Rachel Brazil for Pharmaceutical Journal Publications about: 👉 AI-powered discoveries: Identifying PDE10 as a novel target for ulcerative colitis and advancing BEN-8744 through early-phase clinical trials. 👉 Strategic collaborations: Joining forces with AstraZeneca and Merck Healthcare to accelerate the identification of promising drug candidates. 👉 Innovative NLP capabilities: Pioneering natural language processing tools to draw across the totality of biomedical data and uncover connections beyond human capacity. Read the full article here: https://lnkd.in/gBSNG_at

We have appointed Deutsche Numis as our Financial and Capital Markets Adviser, with immediate effect. Kenneth Mulvany, our Deputy Chair, comments: “We are pleased to appoint Deutsche Numis as our UK and pan-European corporate broker. We look forward to working with their team to maximise our capital markets strategy and realise the true value in BenevolentAI.” Contact details are available here: https://lnkd.in/eg6Z8qad

Following the announcement of our latest AstraZeneca collaboration milestone, we received some great media coverage, including: BioWorld News - ‘AstraZeneca selects SLE target under collaboration with BenevolentAI’: https://lnkd.in/eBJBiGas Endpoints News - ‘AstraZeneca selects lupus target from BenevolentAI deal’: https://lnkd.in/eBGZ5e4e Manufacturing Chemist - ‘BenevolentAI and AstraZeneca collaboration leads to novel lupus target discovery’: https://lnkd.in/eNnNQSPa Thanks also to Stephen Gunnion at Proactive who interviewed our Chief Scientific Officer, Anne Phelan: https://lnkd.in/e2VwQf26

We are delighted to announce further success in our collaboration with AstraZeneca. Using BenevolentAI’s AI-drug discovery platform, a novel target for systemic lupus erythematosus (SLE) has been identified. 🎯 The target has been experimentally validated by AstraZeneca and added to its discovery portfolio. Following the heart failure milestone, it’s the second target to be selected this year from our extended collaboration. 📣 Prof Maria Belvisi, SVP and Head of Research and Early Development Respiratory and Immunology at AstraZeneca said: “By combining our immunology disease area expertise and BenevolentAI’s AI-driven discovery platform, we are increasing our ability to identify new targets based on patient insights, complementing our portfolio of potential treatments for this debilitating disease.” SLE, or lupus, can cause inflammation, pain and damage – often affecting the organs and joints in severe cases. Extreme fatigue and cognitive issues are also common, along with comorbidities including cardiovascular disease. Read more here: https://lnkd.in/e2mq8haw

🗽 Next week our CEO, Joerg Moeller, M.D., will be in New York for the Morgan Stanley 3rd Annual Life Sciences AI Summit. 🎤 Joerg will participate in a panel, Thurs 27 June, 09:55 EST, to discuss value creation with AI for drug discovery, moderated by Vikram Purohit: https://lnkd.in/eUTpmTWY 📬 To arrange a meeting with Joerg and members of our leadership team, contact: investors@benevolent.ai

🎯 ‘A glimpse into the future of AI-driven healthcare’. 🇮🇹 Our Chief Revenue Officer, Christina Busmalis, presented yesterday at the Healthcare Businesswomen’s Association European Leadership Summit in Milan. 💫 A space for thought leaders and healthcare sector experts to connect, learn and grow! #HBAELS24 #HBAImpact

For a special ‘In Conversation’ event this week, we were delighted to welcome Hannah Davies from Crohn's & Colitis UK to our London HQ. Following the milestone success of our in-house pipeline asset for ulcerative colitis (details here: https://lnkd.in/etPrtp7w), Hannah spoke to our CSO, Anne Phelan, about how the disease affects patients - from symptom identification and diagnosis barriers, to the profound impact UC can have on work, relationships and mental health. Hannah and Anne also discussed how innovation and new treatment options could benefit people living with UC. Our sincere thanks to Hannah, who additionally engaged in a compelling Q&A with our team.

Tomorrow, our co-founder Ivan Griffin will participate in AI-Powered Insights: Revolutionizing Pharma BD Deals. Tune in at 2.00 PM GMT / 9.00 AM EST for what promises to be an engaging discussion, also featuring: 👉 Roby Kanichay of Merck Healthcare 👉 Eli Lilly and Company's David Linson 👉 Alexandria Athanasiou Hall from AlphaSense 👉 Steven Lehmann of Portal Innovations, LLC You can register for the free webcast, hosted by LSX - partnering for Life Science eXecutives, here: https://lnkd.in/exb_MbWs

The Goldman Sachs 45th Annual Global Healthcare Conference is fast approaching. As a leading AI-driven drug discovery company, we look forward to discussing our validated industry collaborations and in-house pipeline of high potential assets. Our CEO, Joerg Moeller, M.D., and CFO, Catherine Isted ACMA, will be onsite 11-13 June and will feature in a fireside chat on 13 June, 08:40 AM EDT: https://lnkd.in/eunM7XtB To arrange a meeting, email: investors@benevolent.ai

🇺🇸 We are excited to be attending the 2024 BIO International Convention, 3-6 June, in San Diego. 🚀 Identify and accelerate novel drug discoveries. Come find out about our partnerships and innovative R&D pipeline. 👉 Please reach out to Christina Busmalis or Vern De Biasi to discuss further. #BIO2024